D-0482-2017 Class II Terminated

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-0482-2017 was initiated by RemedyRepack Inc. on Feb 7, 2017 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated May 5, 2017). Affected quantity: 630 pills (21 bottles x 30 pills per HDPE bottle).

Recall details

Product Type
Drugs
Report Date
Mar 1, 2017
Initiation Date
Feb 7, 2017
Termination Date
May 5, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
630 pills (21 bottles x 30 pills per HDPE bottle)

Product description

Glipizide 2.5 mg ER Tablets, Manufactured by Watson Laboratories, Inc., Parsippany, NJ 07054, Repackaged by RemedyRepack, Indiana, PA 15701, NDC 52125-0764-02

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Product was distributed to a sold customer in FL.

Code information

Lot # B0129373-021916; Exp. 10/17 00591-0900-30 Original NDC 52125-0764-02 RemedyRepack NDC

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0482-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0482-2017. Report a data issue: hello@regdatalab.com.